{
    "2018-12-17": [
        [
            {
                "time": "2018-09-10",
                "original_text": "Incyte (INCY) Collaborates with Innovent for 3 Candidates",
                "features": {
                    "keywords": [
                        "collaboration",
                        "Incyte",
                        "Innovent",
                        "candidates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-11",
                "original_text": "Merck to Acquire Europe's Antelliq Group for $2.4 Billion",
                "features": {
                    "keywords": [
                        "acquisition",
                        "Merck",
                        "Antelliq",
                        "billion"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-12",
                "original_text": "7 Major Pharmaceutical Stocks to Quarantine Now",
                "features": {
                    "keywords": [
                        "quarantine",
                        "pharmaceutical",
                        "stocks"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-13",
                "original_text": "Lilly (LLY) to Acquire Pain Candidate From Private Biotech",
                "features": {
                    "keywords": [
                        "acquisition",
                        "Lilly",
                        "pain",
                        "candidate"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc",
                "features": {
                    "keywords": [
                        "dips",
                        "J&J",
                        "asbestos",
                        "talc"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "Better Buy: Eli Lilly and Company vs. Merck & Co.",
                "features": {
                    "keywords": [
                        "better buy",
                        "Eli Lilly",
                        "Merck"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-16",
                "original_text": "Dow Jones Futures: The Worst Part About This Stock Market Rally",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "futures",
                        "rally"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-17",
                "original_text": "Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial",
                "features": {
                    "keywords": [
                        "Taltz",
                        "superior",
                        "Humira",
                        "trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-18",
                "original_text": "Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "positive results",
                        "Taltz",
                        "Humira",
                        "study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-19",
                "original_text": "Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study",
                "features": {
                    "keywords": [
                        "Taltz",
                        "endpoints",
                        "Spirit-H2H",
                        "study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}